双盲安慰剂对照随机临床试验评估孟鲁司特对长新冠患者轻中度呼吸道症状的疗效:E-SPERANZA COVID项目研究方案
该研究为Ⅲ期随机双盲安慰剂对照临床试验,计划纳入18至80岁、SARS-CoV-2感染后轻中度呼吸道症状持续超过4周的長新冠患者,按1:1随机接受口服孟鲁司特10毫克每24小时或安慰剂治疗28天,随访至治疗开始后56天。主要结局为治疗4周时COPD评估测试(CAT)问卷评估的呼吸道症状相关健康生活质量,次要结局包括运动能力、氧饱和度、新冠症状、功能状态、医疗资源使用、死亡率、病假时长及孟鲁司特副作用。
要点
- 该研究为Ⅲ期随机双盲安慰剂对照试验,评估孟鲁司特10毫克每日一次对长新冠轻中度呼吸道症状患者生活质量的影响。
- 主要结局为治疗4周时CAT问卷评估的呼吸道症状相关健康生活质量。
- 纳入标准为18至80岁、SARS-CoV-2感染后轻中度呼吸道症状持续超过4周的患者。
核心结论
- 该研究方案旨在评估口服孟鲁司特10毫克每24小时与安慰剂相比,对改善长新冠患者轻中度呼吸道症状相关生活质量(以CAT问卷测量)的疗效。
研究设计与样本
- Ⅲ期、随机、双盲临床试验,计划纳入18至80岁、SARS-CoV-2感染后轻中度呼吸道症状持续超过4周的患者,按1:1比例随机分配至孟鲁司特10毫克/日组或安慰剂组,治疗28天,随访至治疗开始后56天。
关键数值与推荐
- 主要结局为治疗开始4周后根据COPD评估测试(CAT)问卷评估的呼吸道症状相关健康生活质量。
- 次要结局包括:(a)运动能力和氧饱和度(1分钟坐立试验);(b)新冠后功能状态量表;(c)其他症状:乏力、头痛、精神错乱(脑雾)、味觉丧失和嗅觉丧失(Likert量表);(d)医疗资源使用;(e)死亡率;(f)病假时长(天);(g)孟鲁司特的副作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic continues to affect the globe. After 18 months of the SARS-CoV-2 emergence, clinicians have clearly defined a subgroup of patients with lasting, disabling symptoms. While big strides have been made in understanding the acute phase of SARS-CoV-2 infection, the pathophysiology of long COVID is still largely unknown, and evidence-based, effective treatments for this condition remain unavailable. OBJECTIVES: To evaluate the efficacy of 10 mg oral montelukast every 24 h versus placebo in improving quality of life associated with mild to moderate respiratory symptoms in patients with long COVID as measured with the COPD Assessment Test (CAT) questionnaire. The secondary objectives will evaluate the effect of montelukast versus placebo on improving exercise capacity, COVID-19 symptoms (asthenia, headache, mental confusion or brain fog, ageusia, and anosmia), oxygen desaturation during exertion, functional status, and mortality. METHODS AND ANALYSIS: Phase III, randomized, double-blind clinical trial. We will include 18- to 80-year-old patients with SARS-CoV-2 infection and mild to moderate respiratory symptoms lasting more than 4 weeks. Participants will be randomly allocated in a 1:1 ratio to the intervention (experimental treatment with 10 mg/day montelukast) or the control group (placebo group), during a 28-day treatment. Follow-up will finish 56 days after the start of treatment. The primary outcome will be health-related quality of life associated with respiratory symptoms according to the COPD Assessment Test 4 weeks after starting the treatment. The following are the secondary outcomes: (a) exercise capacity and oxygen saturation (1-min sit-to-stand test); (b) Post-COVID-19 Functional Status Scale; (c) other symptoms: asthenia, headache, mental confusion (brain fog), ageusia, and anosmia (Likert scale); (d) use of healthcare resources; (e) mortality; (f) sick leave duration in days; and (g) side effects of montelukast. ETHICS AND DISSEMINATION: This study has been approved by the Clinical Research Ethics Committee of the IDIAPJGol (reference number 21/091-C). The trial results will be published in open access, peer-reviewed journals and explained in webinars to increase awareness and understanding about long COVID among primary health professionals. TRIAL REGISTRATION: ClinicalTrials.gov NCT04695704 . Registered on January 5, 2021. EudraCT number 2021-000605-24. Prospectively registered.
引用
- Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, et al. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol. Trials. 2022. PMID: 34991703. doi:10.1186/s13063-021-05951-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。